NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Douglas F. Kling Sells 100,000 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Douglas F. Kling sold 100,000 shares of the business’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the completion of the transaction, the chief operating officer now directly owns 44,000 shares in the company, valued at $848,760. This trade represents a 69.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

NewAmsterdam Pharma Trading Down 1.6%

NAMS opened at $18.20 on Thursday. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $27.29. The firm has a 50 day moving average of $18.39 and a two-hundred day moving average of $20.82. The firm has a market capitalization of $2.04 billion, a PE ratio of -9.68 and a beta of -0.03.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The business had revenue of $2.98 million for the quarter, compared to analysts’ expectations of $1.46 million. As a group, analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently modified their holdings of NAMS. Frazier Life Sciences Management L.P. grew its holdings in NewAmsterdam Pharma by 1.3% during the first quarter. Frazier Life Sciences Management L.P. now owns 16,116,418 shares of the company’s stock worth $329,903,000 after acquiring an additional 200,000 shares during the period. Bain Capital Life Sciences Investors LLC lifted its holdings in NewAmsterdam Pharma by 2.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company’s stock valued at $275,481,000 after acquiring an additional 245,197 shares during the period. RA Capital Management L.P. boosted its position in NewAmsterdam Pharma by 14.6% in the 1st quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock worth $207,544,000 after purchasing an additional 1,293,938 shares in the last quarter. Deerfield Management Company L.P. Series C grew its stake in shares of NewAmsterdam Pharma by 378.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company’s stock worth $110,879,000 after purchasing an additional 3,412,590 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of NewAmsterdam Pharma by 53.0% during the 1st quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company’s stock valued at $72,504,000 after purchasing an additional 1,226,852 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an “overweight” rating and a $42.00 price target on the stock. Stifel Nicolaus started coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They issued a “buy” rating and a $44.00 target price on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 30th. Citigroup assumed coverage on NewAmsterdam Pharma in a research report on Tuesday. They issued a “buy” rating and a $42.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.89.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.